Get the Stockscreener App
1.77
4.12%
0.07
After Hours:
1.76
-0.01
-0.56%
Inmune Bio Inc stock is traded at $1.77, with a volume of 302.84K.
It is up +4.12% in the last 24 hours and up +19.59% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$1.70
Open:
$1.72
24h Volume:
302.84K
Relative Volume:
0.74
Market Cap:
$47.06M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-1.0599
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
-3.28%
1M Performance:
+19.59%
6M Performance:
-73.22%
1Y Performance:
-60.58%
1-Day Range:
$1.70
$1.8599
1-Week Range:
$1.70
$1.90
52-Week Range:
$1.38
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.77 | 45.19M | 155.00K | -30.01M | -11.98M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Inmune Bio Amends April 2024 Investor Warrants - TipRanks
How INmune Bio Inc. stock performs in high volatility marketsPrice Action Trading & Accelerated Financial Growth - Bollywood Helpline
INMB (INmune Bio) EV-to-OCF : -0.76 (As of Dec. 22, 2025) - GuruFocus
INMB (INmune Bio) EV-to-FCF : -0.75 (As of Dec. 22, 2025) - GuruFocus
Aug Wrap: How interest rate cuts could boost INmune Bio Inc stockQuarterly Earnings Summary & Real-Time Buy Signal Notifications - moha.gov.vn
Winners Losers: What is the fair value of INmune Bio Inc stock nowChart Signals & Accurate Trade Setup Notifications - moha.gov.vn
Gains Report: Is INmune Bio Inc stock a top pick in earnings seasonQuarterly Portfolio Review & Weekly Watchlist of Top Performers - moha.gov.vn
Why analysts upgrade INmune Bio Inc. stockMarket Performance Recap & Expert Curated Trade Ideas - Улправда
Is INmune Bio Inc. stock vulnerable to regulatory risksMarket Weekly Review & AI Forecasted Stock Moves - Улправда
Can INmune Bio Inc. stock withstand economic slowdown2025 Short Interest & Low Drawdown Trading Strategies - Улправда
Will INmune Bio Inc. stock attract more institutional investorsLayoff News & Smart Money Movement Alerts - Улправда
Aug Highlights: Is INmune Bio Inc. stock attractive for long term wealth buildingWeekly Trading Summary & Verified Technical Trade Signals - Улправда
INMune Bio establishes $65 million at-the-market offering - MSN
Is INmune Bio Inc. stock a good choice for value investorsRecession Risk & Real-Time Buy Zone Alerts - Улправда
INmune Bio Establishes $65 Million At-The-Market Offering - TipRanks
INmune Bio Signs Sales Agreement With A.G.P./Alliance Global Partners - TradingView — Track All Markets
Is INmune Bio Inc. stock resilient to inflation2025 Fundamental Recap & Community Verified Trade Alerts - DonanımHaber
INmune Bio Stock Slumps After Alzheimer’s Drug Falls Short In Mid-Stage Trial - MSN
Is INmune Bio Inc. stock a top pick in earnings season2025 Volatility Report & Consistent Income Trade Ideas - DonanımHaber
INmune Bio Inc Stock Analysis and ForecastCovered Call Writing & Free Short-Term Trading Strategies - earlytimes.in
INmune Bio Shares Collapse After Mixed Results from Alzheimer’s Drug Trial - MSN
INmune Bio Earnings Notes - Trefis
INmune Bio (NASDAQ:INMB) Rating Increased to Hold at Wall Street Zen - MarketBeat
Aug Closing: Is INmune Bio Inc stock resilient to inflationTrade Risk Report & Expert Verified Movement Alerts - moha.gov.vn
Praetorian PR LLC Sells 863,000 Shares of INmune Bio, Inc. $INMB - MarketBeat
Inmune Bio to Host Q3 Results Conference Call - MSN
Inmune Bio Reports Q3 2025 Financial Results - MSN
Inmune Bio Ends Sales Agreement with RBC and BTIG - TipRanks
Can INmune Bio Stock Hold Up When Markets Turn? - Trefis
Can INmune Bio (NASDAQ:INMB) Afford To Invest In Growth? - Sahm
Would You Still Hold INmune Bio Stock If It Fell 30%? - Trefis
Inmune Bio Unveils Promising Alzheimer’s Trial Data - MSN
Insider Sell: Why INmune Bio Inc stock could see breakout soonJuly 2025 Momentum & AI Enhanced Market Trend Forecasts - moha.gov.vn
Retail Trends: Can INmune Bio Inc stock beat analyst upgradesMarket Activity Report & Verified Chart Pattern Signals - BỘ NỘI VỤ
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as Inmune Bio's CORDStrom?? Platform - marketscreener.com
INMB: INmune Bio Highlights Future Potential of MSC Therapies - GuruFocus
INmune Bio, Inc. Announces Publication on Future Applications of Mesenchymal Stromal Cell Therapies - Quiver Quantitative
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform - The Manila Times
Inmune Bio Updates Executive Employment Agreements - TipRanks
INMB SEC FilingsInmune Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Could INmune Bio Unlock Value With Upcoming Regulatory Catalysts And Clinical Readouts? - RTTNews
Why INmune Bio Inc. stock could see breakout soonWeekly Loss Report & Daily Momentum Trading Reports - Newser
Can INmune Bio Inc. stock beat analyst upgradesStock Surge & Free Technical Confirmation Trade Alerts - Newser
Can INmune Bio Stock Recover If Markets Fall? - Trefis
Can INmune Bio Inc. stock sustain revenue growthJuly 2025 News Drivers & AI Powered Buy and Sell Recommendations - Newser
INmune Bio reports promising Alzheimer’s drug data at CTAD conference By Investing.com - Investing.com Canada
INmune Bio stock falls after new Alzheimer’s trial data By Investing.com - Investing.com Nigeria
INmune Bio stock falls after new Alzheimer’s trial data - Investing.com
INmune Bio (INMB) Reveals Promising Phase 2 Neuroimaging Data for Alzheimer's Treatment - GuruFocus
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):